BCPC Stock Overview
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Balchem Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$143.72 |
| 52 Week High | US$159.52 |
| 52 Week Low | US$110.74 |
| Beta | 0.70 |
| 1 Month Change | -7.61% |
| 3 Month Change | 2.89% |
| 1 Year Change | 14.53% |
| 3 Year Change | 15.89% |
| 5 Year Change | 41.58% |
| Change since IPO | 57,340.67% |
Recent News & Updates
Balchem Corporation's (NASDAQ:BCPC) Popularity With Investors Is Clear
Mar 21
Is Balchem Corporation (NASDAQ:BCPC) Expensive For A Reason? A Look At Its Intrinsic Value
Mar 05Balchem: Potential Turnaround Is In The Price
Feb 21Recent updates
Balchem Corporation's (NASDAQ:BCPC) Popularity With Investors Is Clear
Mar 21Is Balchem Corporation (NASDAQ:BCPC) Expensive For A Reason? A Look At Its Intrinsic Value
Mar 05Balchem: Potential Turnaround Is In The Price
Feb 21These 4 Measures Indicate That Balchem (NASDAQ:BCPC) Is Using Debt Reasonably Well
Feb 18Returns On Capital At Balchem (NASDAQ:BCPC) Have Stalled
Jan 03Balchem Corporation's (NASDAQ:BCPC) P/E Is On The Mark
Dec 19Estimating The Fair Value Of Balchem Corporation (NASDAQ:BCPC)
Nov 20Balchem (NASDAQ:BCPC) Has A Pretty Healthy Balance Sheet
Oct 19The Returns At Balchem (NASDAQ:BCPC) Aren't Growing
Sep 09A Look At The Intrinsic Value Of Balchem Corporation (NASDAQ:BCPC)
Aug 22Is Balchem (NASDAQ:BCPC) A Risky Investment?
Jul 19Some Investors May Be Worried About Balchem's (NASDAQ:BCPC) Returns On Capital
May 28Calculating The Fair Value Of Balchem Corporation (NASDAQ:BCPC)
May 12Do Balchem's (NASDAQ:BCPC) Earnings Warrant Your Attention?
Apr 12We Think Balchem (NASDAQ:BCPC) Can Stay On Top Of Its Debt
Mar 14Balchem (NASDAQ:BCPC) Hasn't Managed To Accelerate Its Returns
Jan 11Here's Why We Think Balchem (NASDAQ:BCPC) Is Well Worth Watching
Dec 29Is Balchem (NASDAQ:BCPC) A Risky Investment?
Dec 13Balchem Corporation (NASDAQ:BCPC) Shares Could Be 26% Above Their Intrinsic Value Estimate
Nov 29Here's What To Make Of Balchem's (NASDAQ:BCPC) Decelerating Rates Of Return
Sep 20Balchem: Acquisitions And Cost Pressures Draw Attention
Sep 12Balchem (NASDAQ:BCPC) Seems To Use Debt Rather Sparingly
Sep 05Balchem to acquire Cardinal Associates or Bergstrom Nutrition
Aug 30Is Balchem Corporation (NASDAQ:BCPC) Worth US$138 Based On Its Intrinsic Value?
Aug 22Should You Be Adding Balchem (NASDAQ:BCPC) To Your Watchlist Today?
Aug 08Balchem Q2 2022 Earnings Preview
Jul 28Balchem: On The M&A Road Again
Jun 28Balchem: A New Growth Stage Is Just Beginning
Jun 02Slowing Rates Of Return At Balchem (NASDAQ:BCPC) Leave Little Room For Excitement
May 30Balchem Corporation's (NASDAQ:BCPC) Intrinsic Value Is Potentially 17% Below Its Share Price
May 18Does Balchem (NASDAQ:BCPC) Deserve A Spot On Your Watchlist?
May 02Does Balchem (NASDAQ:BCPC) Have A Healthy Balance Sheet?
Mar 28Balchem (NASDAQ:BCPC) Hasn't Managed To Accelerate Its Returns
Feb 26Balchem (NASDAQ:BCPC) Could Easily Take On More Debt
Dec 23Return Trends At Balchem (NASDAQ:BCPC) Aren't Appealing
Nov 18We Think Balchem (NASDAQ:BCPC) Can Manage Its Debt With Ease
Sep 22Here's What To Make Of Balchem's (NASDAQ:BCPC) Decelerating Rates Of Return
Aug 16Balchem: Good Quarterly Performance Priced In
Aug 02These 4 Measures Indicate That Balchem (NASDAQ:BCPC) Is Using Debt Safely
Jun 12Returns On Capital At Balchem (NASDAQ:BCPC) Have Stalled
May 13Balchem EPS beats by $0.03, beats on revenue
Apr 30Balchem: All Eyes On M&A And Autism Drug
Apr 26Is Balchem (NASDAQ:BCPC) A Risky Investment?
Mar 14How Many Balchem Corporation (NASDAQ:BCPC) Shares Have Insiders Sold, In The Last Year?
Feb 27Shareholder Returns
| BCPC | US Chemicals | US Market | |
|---|---|---|---|
| 7D | -1.3% | -1.1% | -3.2% |
| 1Y | 14.5% | 6.4% | 19.3% |
Return vs Industry: BCPC exceeded the US Chemicals industry which returned 6.4% over the past year.
Return vs Market: BCPC underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| BCPC volatility | |
|---|---|
| BCPC Average Weekly Movement | 3.2% |
| Chemicals Industry Average Movement | 5.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BCPC has not had significant price volatility in the past 3 months.
Volatility Over Time: BCPC's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 1,302 | Ted Harris | www.balchem.com |
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
Balchem Corporation Fundamentals Summary
| BCPC fundamental statistics | |
|---|---|
| Market cap | US$4.64b |
| Earnings (TTM) | US$108.54m |
| Revenue (TTM) | US$922.44m |
42.7x
P/E Ratio5.0x
P/S RatioIs BCPC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCPC income statement (TTM) | |
|---|---|
| Revenue | US$922.44m |
| Cost of Revenue | US$620.38m |
| Gross Profit | US$302.06m |
| Other Expenses | US$193.51m |
| Earnings | US$108.54m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 03, 2024
| Earnings per share (EPS) | 3.36 |
| Gross Margin | 32.75% |
| Net Profit Margin | 11.77% |
| Debt/Equity Ratio | 29.4% |
How did BCPC perform over the long term?
See historical performance and comparison